ES2518490T3 - Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños - Google Patents

Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños Download PDF

Info

Publication number
ES2518490T3
ES2518490T3 ES10744565.2T ES10744565T ES2518490T3 ES 2518490 T3 ES2518490 T3 ES 2518490T3 ES 10744565 T ES10744565 T ES 10744565T ES 2518490 T3 ES2518490 T3 ES 2518490T3
Authority
ES
Spain
Prior art keywords
lactococcus
nutritional composition
infants
children
allergy symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10744565.2T
Other languages
English (en)
Inventor
Sébastien HOLVOET
Annick Mercenier
Adrian Zuercher
Anurag Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42778049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2518490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2518490T3 publication Critical patent/ES2518490T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El uso de cepas de Lactococcus, para la fabricación de un composición nutricional completa, para reducir los síntomas o alérgicas que se originan a partir de los alérgenos aéreos o cutáneos, en pacientes que tengan alergias desencadenadas, respectivamente, por alérgenos alimentarios, aéreos o cutáneos, en donde, la citada composición, proporciona una significativa prevención alérgica secundaria, desencadenada por los citados alérgenos alimentarios, aéreos o cutáneos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
E10744565
20-10-2014
Transcripción inversa:
Se procedió a realizar una transcripción inversa, en 1 µg de RNA total, mediante la utilización de un equipo de ensayo, a modo de “kit”, de transcriptasa inversa Multiscribe, del tipo “Multiscribe Reverse Transcriptase kit” (Applied 5 Biosystems, Foster City, CA, USA). El RNA total, se mezcló con 50 µM de hexámeros aleatorios, 0,5 mM de dNTPs, 20 U de inhibidor de RNasa (Applied Biosystems), 62,5 U de transcriptasa inversa Multiscribe, 1 X tampón RT, y 5,5 mM de MgCl2, en un volumen final de 50 µl. La transcripción inversa, se realizó en un termociclizador del tipo “T3 thermocycler” (Biometra, Göttingen, Alemania), con el siguiente programa de los ciclos: 10 minutos a una temperatura de 25 °C, 30 minutos a una temperatura de 48 °C, 5 minutos a una temperatura de 95 °C, par a finalizar
10 a una temperatura de 4 °C.
Serie de baja densidad (LDA):
Se procedió a diseñar series de baja densidad, “online” (en línea), en la website (dirección informática) de Applied
15 Biosytems (http://www3.appliedbiosystems.com/index.htm). La carga, la serie y el análisis, se llevaron a cabo en concordancia con el protocolo del fabricante, en un dispositivo cuantitativo del tipo “quantitative ABI-Prism 7900HT”.
La cuantificación, se normalizó con la media de 3 genes del tipo “housekeeping gen”: β-actina, GAPDH y HPRT. En base a los valores obtenidos del ciclo umbral (Ct), se determinó una relativa y normalizada expresión de mRNA, para
20 cada gen, mediante la utilización del ΔCt. Se procedió a corregir el valor del Ct medio de tres genes del tipo “housekeeping gen”. Los resultados obtenidos, se calcularon como una expresión relativa, mediante la utilización de la fórmula 2 -ΔCt x K, en donde, K, es un factor 106. Los resultados incrementados de la multiplicación de la expresión, se normalizaron a los niveles de expresión, en el grupo Negativo.
25 Ejemplo 1:
Un ejemplo de la composición para lactantes o bebés, para su uso en concordancia con la presente invención, es la que se proporciona abajo, a continuación. Esta composición, se proporciona únicamente a título de ilustración. La fuente de proteínas, es una mezcla convencional de proteína de trigo y de caseína.
30
Nutriente
Por 100 kcal Por litro
Energía (kcal)
100 670
Proteína (g)
1,83 12,3
Grasa (g)
5,3 35,7
Ácido linoleico (g)
0,79 5,3
Ácido α-linolénico (mg)
101 675
Lactosa (g)
11,2 74,7
Prebiótico (100 % COS) (g)
0,64 4,3
Minerales (g)
0,37 2,5
Na (g)
23 150
K (mg)
89 590
Cl (mg)
64 430
Ca (mg
62 410
P (mg)
31 210
Mg (mg)
7 50
Mn (µg)
8 50
Se (µg)
2 13
16 E10744565
20-10-2014
Vitamina A (µg RE)
105 700
Vitamina D (µg)
1,5 10
Vitamina E (mg TE)
0,8 5,4
Vitamina K1 (µg)
8 54
Nutriente
Por 100 kcal Por litro
Vitamina C (mg)
10 67
Vitamina B1 (mg)
0,07 0,47
Vitamina B2 (mg)
0,15 1,0
Niacina (mg)
1 6,7
Vitamina B6 (mg)
0,075 0,50
Ácido fólico (µg)
9 60
Ácido pantoténico (mg)
0.45 3
Vitamina B12 (µg)
0,3 2
Biotina (µg)
2,2 15
Colina (mg)
10 67
Fe (mg)
1,2 8
I (µg)
15 100
Cu (mg)
0,06 0,4
Zn (mg)
0,75 5
Lactococcus lactis NCC 2287 (SL131; Veáse la parte experimental)
2 x 107 UFC / g de material en polvo
Ejemplo 2:
Ejemplo de la composición de la invención: Leche en polvo adaptada, pretendida para niños. Esta composición, es una ilustración de la invención.
Nutriente
Por 100 kcal Por litro
Energía (kcal)
100 670
Proteína (g)
3,66 24,5
Grasa (g)
4,52 30,2
Ácido linoleico (g)
0,69 4,6
Ácido α-linolénico (mg)
73 490
Hidratos de carbono (g)
11,18 74,9
Prebiótico (100 % COS) (g)
0,64 4,3
17
imagen15
imagen16
E10744565
20-10-2014
corta, la mananoligofructosa, la fibra de soja, el arabinogalactano, el galactooligosacárido, el arabinoxilano, o mezclas de entre éstos.
De una forma alternativa, la fuente de fibras, pude ser una fuente fermentable. La fibra fermentable, según se ha
5 descrito anteriormente, proporciona un beneficio al sistema inmune de un animal de compañía o mascota. La fibra fermentable, u otros composiciones, las cuales, según se conoce bien, bien, por parte de aquéllas personas usualmente expertas en el arte especializado de la técnica, proporcionan un prebiótico para mejorar el crecimiento de los probióticos, en el interior de los intestinos, puede también incorporarse en la composición, con objeto ayudar en la mejora del beneficio proporcionado por la presente invención en el sistema inmune de un animal.
10 En algunas formas de presentación, el contenido de cenizas en la composición alimenticia, es el correspondiente a unos porcentajes comprendidos dentro de unos márgenes que van desde menos de un 1 % hasta un aprox. un 15%, siendo dicho contenido, de una forma preferible, el correspondiente a unos porcentajes comprendidos dentro de unos márgenes que van desde aprox. un 5 % hasta aprox. un 10%.
15 En una forma preferida de presentación, la composición, es una composición alimenticia, con un porcentaje de proteína, correspondiente a un valor comprendido dentro de unos márgenes que van desde aprox. un 15 % hasta aprox. un 50%, un porcentaje de grasa, correspondiente a un valor comprendido dentro de unos márgenes que van desde aprox. un 5 % hasta aprox. un 40%, un porcentaje de cenizas, correspondiente a un valor comprendido dentro
20 de unos márgenes que van desde aprox. un 5 % hasta aprox. un 10%, y la cual tiene un contenido de humedad, la cual es la correspondiente a un valor comprendido dentro de unos márgenes que van desde aprox. un 5 % hasta aprox. un 20%. En una forma de presentación, la composición alimenticia, comprende adicionalmente prebióticos o probióticos, de la forma que se ha descrito aquí, en este documento.
25 PCT
0 -1 0 – 1 -1
Forma PCT / RO / 134 (SAFE) Indicaciones relativas al (a los) Microorganismo(s)) u otro Material Biológico depositadado(s) (PCT Rule 13bis) Preparados mediante la utilización de PCT Online Filing Version 3.5.000.221 MT/FOP
0 – 2
Solicitud Internacional Nº
0 -3
Referencia del archive del solicitante o del agente 10101 – WO -PCT
1
Las indicaciones proporcionadas posteriormente, abajo, se refieren al (a los) microorganismo(s) depositado(s) u otro material biológico a los que se hace referencia en la descripción, en
RO/EP*1 – 1
página 7*
1 – 2
línea 28*
1 – 3
Identificación de depósito:
1 – 3 – 1
Nombre de la institución depositaria CNCM Collection nationale de cultures de micro-organismes
1 – 3 – 2
Dirección de la institución depositaria Insitut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, Francia
1 – 3 – 3
Fecha de depósito 09 de Septiembre del 2009 (09.09.2009)
1 – 3 -4
Número de acceso CNCM 4227
1 – 5
Estados designados para los cuales se han realizado la indicaciones Todas las designaciones
2
Las indicaciones proporcionadas posteriormente, abajo, se refieren al (a los) microorganismo(s) depositado(s) u otro material biológico a los que se hace referencia en la descripción, en
RO/EP*2 – 1
página 7*
2 – 2
línea 27*
2 – 3 2 – 3 – 1
Identificación de depósito: Nombre de la institución depositaria CNCM Collection nationale de cultures de micro-organismes
20
imagen17

Claims (1)

  1. imagen1
    imagen2
ES10744565.2T 2009-08-18 2010-08-13 Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños Active ES2518490T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09168053 2009-08-18
EP09168053 2009-08-18
EP09170599 2009-09-17
EP09170599 2009-09-17
PCT/EP2010/061803 WO2011020780A1 (en) 2009-08-18 2010-08-13 A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children.

Publications (1)

Publication Number Publication Date
ES2518490T3 true ES2518490T3 (es) 2014-11-05

Family

ID=42778049

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10744565.2T Active ES2518490T3 (es) 2009-08-18 2010-08-13 Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños

Country Status (16)

Country Link
US (1) US9049881B2 (es)
EP (1) EP2467031B1 (es)
CN (1) CN102695427B (es)
AU (1) AU2010285068B2 (es)
BR (1) BR112012003706A2 (es)
CA (1) CA2770099A1 (es)
CL (1) CL2012000417A1 (es)
ES (1) ES2518490T3 (es)
IN (1) IN2012DN00878A (es)
MX (1) MX2012002039A (es)
PL (1) PL2467031T3 (es)
PT (1) PT2467031E (es)
SG (1) SG178139A1 (es)
TW (1) TW201117733A (es)
WO (1) WO2011020780A1 (es)
ZA (1) ZA201202009B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
EP2510932A1 (en) * 2011-04-15 2012-10-17 Nestec S.A. Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny
MX2014000458A (es) * 2011-07-12 2014-05-01 Nestec Sa Probioticos para la administracion a mamiferos jovenes saludables durante el periodo de destete para mejorar l atolerancia a productos alimenticios de introduccion reciente.
US20130084271A1 (en) * 2011-10-03 2013-04-04 Kelly Foods Corporation Probiotic composition for pets and method of providing the same
EP2617296A1 (en) 2012-01-19 2013-07-24 Nestec S.A. A composition comprising specific Lactobacillus helveticus strains and reducing food and/or respiratory allergy symptoms
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
US20150352162A1 (en) 2013-01-21 2015-12-10 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
KR102379658B1 (ko) 2013-11-25 2022-03-28 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
SG11201706734SA (en) * 2015-02-20 2017-09-28 Univ Leland Stanford Junior Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
WO2019178325A1 (en) 2018-03-14 2019-09-19 Emory University Lactococcus bacteria and uses thereof
CN109212129A (zh) * 2018-06-30 2019-01-15 湖北海纳天鹰科技发展有限公司 一种规避空气中过敏原的目的地选择方法和装置
CN113507844A (zh) 2019-01-23 2021-10-15 前品牌股份有限公司 制备混合型过敏原组合物的方法
EP4297736A1 (en) * 2021-02-23 2024-01-03 Société des Produits Nestlé S.A. Composition and kit for alleviating symptoms of respiratory allergy in toddlers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946488B2 (ja) 1978-08-07 1984-11-13 極東脂肪酸株式会社 アレルギ−反応抑制剤
GB2077101B (en) 1980-05-12 1984-08-08 Kyokuto Fatty Acid Corp Antiallergic composition containing streptococci
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
CN1149969A (zh) 1996-09-18 1997-05-21 任圣启 类母乳系列保健产品的制造技术
EP0862863B9 (en) * 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP4308481B2 (ja) 2002-06-18 2009-08-05 独立行政法人農業・食品産業技術総合研究機構 抗アレルギー剤
AU2004227998A1 (en) * 2003-04-02 2004-10-21 Pharmachem Laboratories, Inc. Novel probiotic compositions and methods of using the same
JP4589618B2 (ja) * 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
JP2006028050A (ja) 2004-07-14 2006-02-02 Combi Corp 皮膚アレルギー抑制組成物
WO2006097949A1 (en) 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US20080003329A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
EP1964570B1 (de) * 2007-03-02 2012-11-21 Protectimmun GmbH Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
CA2684001A1 (en) * 2007-04-27 2008-11-06 Naked Juice Co. Of Glendora, Inc. Fruit juice beverages with probiotic bacteria
CN101328468B (zh) * 2007-06-21 2012-05-23 东宇生物科技股份有限公司 抗过敏的乳酸菌
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
JP2009060800A (ja) 2007-09-04 2009-03-26 Tsujido Kagaku Kk 食品組成物
PL2234505T3 (pl) * 2007-12-21 2013-06-28 Nutricia Nv Zastosowanie sfingomieliny i nietrawionych węglowodanów do poprawy mikroflory jelitowej

Also Published As

Publication number Publication date
WO2011020780A1 (en) 2011-02-24
AU2010285068B2 (en) 2015-05-28
CL2012000417A1 (es) 2012-09-28
CA2770099A1 (en) 2011-02-24
US20120148629A1 (en) 2012-06-14
ZA201202009B (en) 2014-08-27
MX2012002039A (es) 2012-04-11
RU2012110168A (ru) 2013-09-27
PL2467031T3 (pl) 2015-03-31
CN102695427A (zh) 2012-09-26
EP2467031A1 (en) 2012-06-27
EP2467031B1 (en) 2014-09-24
AU2010285068A1 (en) 2012-03-29
TW201117733A (en) 2011-06-01
CN102695427B (zh) 2016-04-13
BR112012003706A2 (pt) 2015-09-01
SG178139A1 (en) 2012-03-29
US9049881B2 (en) 2015-06-09
IN2012DN00878A (es) 2015-05-22
PT2467031E (pt) 2014-10-30

Similar Documents

Publication Publication Date Title
ES2518490T3 (es) Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños
Li et al. Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation
Simms-Waldrip et al. Antibiotic-induced depletion of anti-inflammatory clostridia is associated with the development of graft-versus-host disease in pediatric stem cell transplantation patients
Sun et al. Chronic exposure to dietary antibiotics affects intestinal health and antibiotic resistance gene abundance in oriental river prawn (Macrobrachium nipponense), and provokes human health risk
Rudzki et al. Gut microbiota-derived vitamins–underrated powers of a multipotent ally in psychiatric health and disease
Yin et al. Dietary administration of laminarin improves the growth performance and immune responses in Epinephelus coioides
Ji et al. Dietary proline supplementation alters colonic luminal microbiota and bacterial metabolite composition between days 45 and 70 of pregnancy in Huanjiang mini-pigs
Grabinger et al. Alleviation of intestinal inflammation by oral supplementation with 2-fucosyllactose in mice
Justino et al. Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice
JP2022000040A (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
Merrifield et al. The current status and future focus of probiotic and prebiotic applications for salmonids
Van der Meij et al. Nutritional support in patients with GVHD of the digestive tract: state of the art
Ramakrishnan et al. Effects of probiotics and spirulina on survival and growth of juvenile common carp (Cyprinus carpio)
Garrido-Mesa et al. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties
ABdel‐Tawwab et al. Use of live baker's yeast, Saccharomyces cerevisiae, in practical diet to enhance the growth performance of Galilee tilapia, Sarotherodon galilaeus (L.), and its resistance to environmental copper toxicity
WO2010036876A2 (en) Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
TWI636788B (zh) 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
Schei et al. Early gut fungal and bacterial microbiota and childhood growth
Munaeni et al. Impact of dietary supplementation with Eleutherine bulbosa (Mill.) Urb. on intestinal microbiota diversity and growth of white shrimp, Litopenaeus vannamei
Seenivasan et al. Effect of Lactobacillus sporogenes on survival, growth, biochemical constituents and energy utilization of freshwater prawn Macrobrachium rosenbergii post larvae
Mehrgan et al. Synergistic effects of sodium butyrate and sodium propionate on the growth performance, blood biochemistry, immunity, and immune-related gene expression of goldfish (Carassius auratus)
Fatholahi et al. Nano-Bio zinc synthesized by Bacillus subtilis modulates broiler performance, intestinal morphology and expression of tight junction's proteins
Liu et al. Impacts of varying methionine to cysteine supplementation ratios on growth performance, oxidative status, intestinal health, and gene expression of immune response and methionine metabolism in broilers under Eimeria spp. challenge
Kang et al. Therapeutic and preventive effect of orally administered prebiotics on atopic dermatitis in a mouse model
Bergeron et al. Antioxidant status and inflammatory response in weanling piglets fed diets supplemented with arginine and zinc